The New Product Planning Manager is a high impact role that will support the strategy, planning and execution of commercial assessments for Genesis’s AI-enabled pipeline programs. The position will report to the Director of New Product Planning. This role will be hybrid 2-3 days a week based at Genesis’s San Diego office. Key Responsibilities: - Market analysis: Analyze disease areas, treatment paradigms, and unmet needs to help shape the positioning of new potential drugs - Primary and secondary research: Support KOL interviews, along with secondary research such as epidemiology and published literature, to build and validate commercial assumptions - Competitive monitoring: Track competitor pipelines, clinical readouts, approvals, and deals, including monitoring conference abstracts and presentations for early signals, and translate the implications into updated assumptions for the team - Development strategy: Contribute commercial input into Target Product Profiles (TPPs) and clinical development plans (endpoints, comparators, patient populations, and indication sequencing) - Cross-functional collaboration: Work with discovery, preclinical development, business development, and finance to keep programs aligned with commercial objectives Candidate profile: - Life sciences background, ideally a BS or MS degree in biology or a related field - 1-2 years at a top-tier consulting firm, investment bank, or equity research group preferred - Experience in New Product Planning, marketing, portfolio strategy, competitive intelligence, or a related analytical role at a pharmaceutical or biotech company also considered - Experience in oncology or immunology is a plus - Some exposure to commercial assessments based on primary and secondary research, ideally for preclinical and early clinical assets - Strong Excel modeling and PowerPoint skills - Excellent communication, listening, and presentation skills - Ability to travel domestically and internationally, if required, approximately 10% of the time About Genesis Molecular AI Genesis Molecular AI http://genesis.ml is pioneering foundation models for molecular AI to unlock a new era of drug design and development. Our generative and predictive AI platform, GEMS (Genesis Exploration of Molecular Space), integrates AI and physics into industry-leading models to generate and optimize drug molecules, including the breakthrough generative diffusion model Pearl https://www.businesswire.com/news/home/20251028030745/en/Genesis-Molecular-AI-Unveils-Pearl-a-Field-Leading-Foundation-Model-that-Achieves-Unprecedented-Performance-in-Drug-Protein-Structure-Prediction for structure prediction. Genesis is backed by premier AI and life science investors, including a16z, NVIDIA, Rock Springs Capital, Menlo Ventures, T. Rowe Price, Fidelity, and Radical Ventures. Genesis has also signed category-leading AI-pharma deals, the most recent of which was a significant expansion with Incyte (see coverage in Forbes https://www.forbes.com/sites/innovationrx/2026/05/20/inside-incytes-120-million-ai-for-drug-development-deal/ and GEN https://www.genengnews.com/topics/artificial-intelligence/small-molecules-to-big-partnership-incyte-genesis-expand-ai-collaboration-to-1b/) with a total potential deal value of several billion dollars. Genesis is headquartered in San Mateo, CA, with a fully integrated laboratory in San Diego. We are proud to be an inclusive workplace and an Equal Opportunity Employer.